RPG Life Sciences deploys ₹500 crore for API expansion
RPG Life Sciences is targeting 25% annual growth in its API business, planning a new acquisition within a year using a ₹500 crore capital pool.

RPG Life Sciences is scaling its API business through strategic acquisitions and partnerships to achieve 25% annual growth. The Mumbai-based integrated pharmaceutical company plans to deploy approximately ₹500 crore from its committed capital pool for another acquisition within the next 12 months.
The company transferred its API business to RPG Active Pharma, a wholly owned subsidiary, and onboarded private equity firm InvAscent as a strategic partner. It aims for a 25% compounded annual growth rate over the next five years through organic expansion and acquisitions. Two acquisitions have already been completed to strengthen the API business.
Recent Acquisition Impact
The acquisition of Actis Therapeutics and Raghav Lifesciences has significantly boosted manufacturing capacity and customer base. Backed by InvAscent, these buys are expected to contribute revenue by the third quarter of the 2027 financial year.
The acquisitions expanded manufacturing capacity fivefold and doubled the customer base. Actis and Raghav Lifesciences are expected to contribute between ₹70 crore and ₹80 crore in revenue over the next six months.
Financial Performance and Growth
The company reported strong second-quarter growth with 16.5% year-on-year revenue growth to ₹211.6 crore, crossing ₹200 crore for the first time. It reported its highest-ever adjusted operating profit.
Adjusted Ebitda grew 15%, excluding one-time acquisition costs, and gross margins expanded 260 basis points. Profit before tax grew by 11%. The domestic business grew 13% in the first half of the year, against industry growth of 11%. Volumes grew by 6.8% in the quarter.
Managing Director Ashok Nair attributed margin expansion to an improved product mix, strategic inventory building, and price increases, despite higher freight, solvent and packaging costs linked to the West Asia conflict. The company jumped 12 ranks in the Indian Pharmaceutical Market since March 2025, becoming one of the top 50 companies and the fourth-fastest-growing company in the market.
Regulatory and Market Challenges
The company handles government trade margin caps on cancer drugs while maintaining pricing stability for customers. RPG Life Sciences does not expect a material impact on sales or margins from the government’s 30% trade margin cap on certain cancer medicines.
Maximum retail prices for oncology brands like Ivzumab, Densurak, Denbri, and Debrumab must be reduced, but the company’s selling prices will remain broadly unchanged. The company believes lower prices for patients could improve treatment access and support oncology volumes over time, improving affordability across its specialty portfolio.
The company aims to generate around ₹450 crore in revenue from existing manufacturing facilities without significant additional investment. Growth is expected from higher capacity utilisation, new customers, and entry into Europe and South America markets. It is becoming stronger in regulated foreign markets in Europe and Canada, and new markets such as Latin America and Africa, having secured tenders in some Latin American markets and completed its first contract development and manufacturing organization project on time.
Ashok Nair stated the company is looking for an asset with USFDA approval or synergies with existing operations for its next acquisition. It has already deployed around ₹200 crore from its ₹700-crore committed capital pool. The company aims to sustain its growth trajectory, supported by domestic formulations, acquisitions, and a recovery in its international formulations business. It also plans to leverage its network of specialist doctors in nephrology and rheumatology to promote its generic semaglutide. The company plans to acquire another asset within the next 12 months to continue API business scaling.





